Form 4: Teva Director Chen Lichtenstein Acquires 4,804 Restricted Share Units

Teva Pharmaceutical Industries director Chen Lichtenstein was granted 4,804 restricted share units on December 2, 2024, which vest on December 2, 2025.

Summary

• Chen Lichtenstein, a director at Teva Pharmaceutical Industries, was granted 4,804 restricted share units on December 2, 2024.
• These restricted share units represent a contingent right to receive one ordinary share or the cash equivalent at settlement.
• The restricted share units will vest on December 2, 2025.
• The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications or surprises.

Positives

• The grant of restricted share units aligns the director's interests with the company's performance.
• The vesting period of one year encourages long-term commitment from the director.

Future Outlook

The restricted share units will vest on December 2, 2025, at which point the director will receive ordinary shares or their cash equivalent.

Industry Context

The granting of restricted share units is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the company's long-term performance.

Comparison to Industry Standards

• Equity-based compensation, such as restricted share units, is a standard practice among publicly traded companies, including pharmaceutical firms like Pfizer, Johnson & Johnson, and AbbVie.
• These companies often use a mix of stock options, restricted stock, and performance-based equity awards to align executive compensation with shareholder value creation.
• The vesting period of one year is relatively standard, although some companies may use longer vesting periods to further incentivize long-term performance.

Stakeholder Impact

• The grant of restricted share units may have a slightly positive impact on shareholders as it aligns the director's interests with the company's long-term success.
• The vesting of the shares will increase the number of shares outstanding, which could have a minor dilutive effect.

Key Dates

Keywords

restricted share units, Teva Pharmaceutical Industries, Chen Lichtenstein, director, share grant, equity compensation, vesting